Aaron Wealth Advisors LLC Cuts Stock Holdings in Eli Lilly and Company $LLY

Aaron Wealth Advisors LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 7.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,253 shares of the company’s stock after selling 943 shares during the period. Eli Lilly and Company comprises about 0.6% of Aaron Wealth Advisors LLC’s portfolio, making the stock its 28th biggest holding. Aaron Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $10,350,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $12,976,634,000. Capital Research Global Investors increased its stake in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP raised its holdings in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after purchasing an additional 4,038,502 shares during the period. Cardano Risk Management B.V. raised its holdings in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LLY shares. Weiss Ratings cut Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Guggenheim reissued a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,235.07.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,206.51 on Friday. The stock has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 42.86, a price-to-earnings-growth ratio of 1.32 and a beta of 0.53. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,215.76. The firm has a 50-day simple moving average of $1,036.28 and a 200-day simple moving average of $1,020.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.